pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.
3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US HQ
2020 Founded
506 Employees
Public company Type
TVTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Travere Therapeutics clinical trials
Registry index of 18 ClinicalTrials.gov studies linked to Travere Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Travere Therapeutics trial registry — 18 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Travere Therapeutics.
-
TVTX-TVT058-301 — Phase 3
Clinical update -
RTRX-RE021-201 — Phase 2
Clinical update -
021IGAN17001 — Phase 3
Clinical update -
021FSGS16010 — Phase 3
Clinical update -
Fosmetpantotenate — Phase 3
Clinical update -
Pegtibatinase — Phase 3
Clinical update -
sparsentan — Phase 3
Clinical update -
sparsentan — Phase 3
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2023-505497-14-00CTIS ↗
RTRX-RE021-201
Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗